STANDARD BIOTOOLS INC. — Director's Dealing 2024

Apr 6, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: STANDARD BIOTOOLS INC. (LAB)
CIK: 0001162194
Period of Report: 2024-01-05

Reporting Person: Egholm Michael (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-01-05	Common Stock	A	9006	—	Acquired	225518	Direct
2024-04-04	Common Stock	M	196512	—	Acquired	422030	Direct
2024-04-05	Common Stock	A	212126	—	Acquired	634156	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-04-04	Restricted Stock Units	$	M	196512	Disposed		Common Stock (196512)	Direct

Footnotes

F1: Received in exchange for 8,114 shares of common stock of SomaLogic, Inc. ("SomaLogic") pursuant to the Agreement and Plan of Merger, dated October 4, 2023, by and among Standard BioTools Inc. (the "Issuer"), Martis Merger Sub, Inc. and SomaLogic (the "Merger"). Per the terms of the Merger, each share of SomaLogic common stock was converted into the right to receive 1.11 shares of the Issuer's common stock at the effective time of the Merger.

F2: On April 11, 2023, the Reporting Person was granted a target amount of 231,579 performance-based restricted stock units ("RSUs") under the Issuer's 2011 Equity Incentive Plan, as amended. Each RSU represent the right, upon achievement of certain pre-established performance criteria, to receive one share of the Issuer's common stock, subject to vesting conditions. On April 5, 2024, the Board of Directors of the Issuer determined that certain of the RSU performance-based conditions were met resulting in the vesting of 212,126 RSUs as of March 31, 2024.

F3: Each RSU represents the contingent right to receive one share of the Issuer's common stock.

F4: On April 4, 2022, the Reporting Person was granted 786,049 RSUs, vesting in four equal annual installments beginning on April 4, 2023.